ICON Public (NASDAQ:ICLR) Upgraded by Deutsche Bank Aktiengesellschaft to Buy

ICON Public (NASDAQ:ICLRGet Rating) was upgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating in a report released on Monday, The Fly reports.

ICLR has been the subject of several other reports. StockNews.com assumed coverage on ICON Public in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Mizuho dropped their price objective on ICON Public from $315.00 to $272.00 and set a “buy” rating for the company in a research report on Monday, March 7th. Barclays lowered their target price on ICON Public from $285.00 to $255.00 and set an “equal weight” rating for the company in a report on Wednesday, February 23rd. TheStreet cut ICON Public from a “b-” rating to a “c” rating in a report on Thursday, March 10th. Finally, Zacks Investment Research raised ICON Public from a “sell” rating to a “hold” rating in a research note on Tuesday, March 8th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $272.60.

ICLR traded down $13.60 during midday trading on Monday, reaching $247.72. 645,761 shares of the company were exchanged, compared to its average volume of 661,081. ICON Public has a one year low of $193.25 and a one year high of $313.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.19 and a current ratio of 1.19. The stock has a market capitalization of $20.16 billion, a P/E ratio of 83.97, a PEG ratio of 1.40 and a beta of 0.98. The stock’s 50-day simple moving average is $242.07 and its 200 day simple moving average is $264.82.

ICON Public (NASDAQ:ICLRGet Rating) last announced its earnings results on Tuesday, February 22nd. The medical research company reported $2.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.40 by $0.04. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.90 billion. ICON Public had a return on equity of 12.71% and a net margin of 2.79%. ICON Public’s revenue for the quarter was up 148.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 EPS. On average, research analysts anticipate that ICON Public will post 10.71 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the business. Whittier Trust Co. of Nevada Inc. boosted its position in shares of ICON Public by 223.5% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 110 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares in the last quarter. Lindbrook Capital LLC lifted its position in ICON Public by 86.7% in the 4th quarter. Lindbrook Capital LLC now owns 168 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 78 shares in the last quarter. Titleist Asset Management LTD. bought a new position in shares of ICON Public during the 4th quarter valued at $201,000. Jag Capital Management LLC bought a new position in shares of ICON Public during the 4th quarter valued at $206,000. Finally, KB Financial Partners LLC lifted its holdings in shares of ICON Public by 21.3% during the 3rd quarter. KB Financial Partners LLC now owns 804 shares of the medical research company’s stock valued at $211,000 after buying an additional 141 shares during the period. Hedge funds and other institutional investors own 88.40% of the company’s stock.

About ICON Public (Get Rating)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

See Also

The Fly logo

Analyst Recommendations for ICON Public (NASDAQ:ICLR)

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.